Clinical trial · Observational
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study never moved past ideation phase
Summary
Brief summary (as posted)
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer. For some patients, the removal of a lobe of lung may leave too little lung behind for easy breathing. For some of these patients, it may be possible to perform a smaller-scale surgery ("sub-lobar resection") and place a radioactive implant behind to prevent the cancer from growing back. This study will see how these patients do in terms of controlling their disease treated with a radioactive implant called Cesium-131.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cesium-131 Brachytherapy Seed | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Sub-lobar resection with Cesium-131
- description
- All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
- interventionNames
- Radiation: Cesium-131 Brachytherapy Seed
Primary outcomes (1)
- measure
- Local Recurrence
- timeFrame
- 3 Years
- description
- Cancer regrowth in the area where it was surgically removed
Secondary outcomes (1)
- measure
- Quality of Life
- timeFrame
- 2 years
- description
- Using questionnaires, data will be collected related to the sense of well-being experienced by the patient after treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients must have suspicious lung nodule for clinical stage I/recurrent non-small cell Lung Cancer 2. Mass Tumor size \< 7 cm 3. Patient must have a CT scan of the chest with upper abdomen within 90 days prior to date of pre-registration. 4. Patient must have ECOG/Zubrod performance status 0,1, or 2. Exclusion Criteria: 1. Patient has already received high dose radiation to the area 2. Cancerous nodule is very close to the esophagus or spinal cord, thereby increasing the risk of radiation treatment 3. Pregnancy or unwillingness to practice a form of birth control (i.e. abstinence, oral contraceptives, etc.)
References
Publications (0)
Data not yet available